Barclays lowered the firm’s price target on Crispr Therapeutics to $56 from $64 and keeps an Equal Weight rating on the shares. The company’s Q3 update largely incremental, with on-track pipeline progress, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- Crispr Therapeutics reports Q3 EPS ($1.41), consensus ($1.95)
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- Crispr Therapeutics options imply 5.7% move in share price post-earnings
- CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
- Biotech Alert: Searches spiking for these stocks today